New adaptive chemo strategy aims to outsmart advanced breast cancer

NCT ID NCT07088263

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way of giving chemotherapy called adaptive therapy for people with advanced breast cancer that has gotten worse after standard treatments. The goal is to see if adjusting the dose over time can help control the cancer longer and with fewer side effects. About 192 adults with specific types of breast cancer (HR+/HER2- or HR-/HER2-) will take part. The main focus is on how long the cancer stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.